Open Access

Fulminant Staphylococcus lugdunensis septicaemia following a pelvic varicella-zoster virus infection in an immune-deficient patient: a case report

  • M Woznowski1,
  • I Quack1,
  • E Bölke2,
  • M Peiper3,
  • C Matuschek2,
  • SG Gatermann4,
  • LC Rump1 and
  • G Schieren1Email author
European Journal of Medical Research201015:410

https://doi.org/10.1186/2047-783X-15-9-410

Received: 26 February 2010

Accepted: 19 April 2010

Published: 24 September 2010

Abstract

Introduction

The deadly threat of systemic infections with coagulase negative Staphylococcus lugdunensis despite an appropriate antibiotic therapy has only recently been recognized. The predominant infectious focus observed so far is left-sided native heart valve endocarditis, but bone and soft tissue infections, septicaemia and vascular catheter-related bloodstream infections have also been reported. We present a patient with a fatal Staphylococcus lugdunensis septicaemia following zoster bacterial superinfection of the pelvic region.

Case presentation

A 71-year old male diagnosed with IgG kappa plasmocytoma presented with a conspicuous weight loss, a hypercalcaemic crisis and acute renal failure. After initiation of haemodialysis treatment his condition improved rapidly. However, he developed a varicella-zoster virus infection of the twelfth thoracic dermatome requiring intravenous acyclovir treatment. Four days later the patient presented with a fulminant septicaemia. Despite an early intravenous antibiotic therapy with ciprofloxacin, piperacillin/combactam and vancomycin the patient died within 48 hours, shortly before the infective isolate was identified as Staphylococcus lugdunensis by polymerase chain reaction.

Conclusion

Despite S. lugdunensis belonging to the family of coagulase-negative staphylococci with an usually low virulence, infections with S. lugdunensis may be associated with an aggressive course and high mortality. This is the first report on a Staphylococcus lugdunensis septicaemia following a zoster bacterial superinfection of the pelvic region.

Introduction

Staphylococcus lugdunensis was first described in 1988 [1]. It belongs to the family of coagulase-negative staphylococci (CoNS), which are skin commensals and historically regarded as pathogens of low virulence. Despite their resistance to a large number of antibiotics, infections with CoNS clinically manifest as less severe, subacute diseases with a low mortality rate [2]. In contrast to other CoNS, S. lugdunensis infections exhibit a particular aggressive course associated with a high mortality. Thus S. lugdunensis, although a CoNS, should be regarded as equivalent to S. aureus when considering the pathogenic potential. [3]. S. lugdunensis is a member of the normal skin flora and colonizes predominantly the perineal region, especially the inguinal folds [46]. Infectious isolates are mostly derived from skin- and less frequently from vascular-related infections. This pathogen occurs in patients with underlying diseases, especially immunosuppressed patients [711], but has also been described in otherwise healthy people [5, 12, 13]. Due to the susceptibility of S. lugdunensis to a large number of antimicrobial agents, these infections are often underestimated in their severity by physicans - explaining why S. lugdunensis is also called 'a wolf in sheep's clothing' [13].

Here, we report a case of fulminant and fatal septicaemia with S. lugdunensis following a pelvic varicella-zoster virus infection in an immunodeficient patient. Despite early and appropriate antibiotic treatment, the patient died within 48 hours.

Case presentation

A 71 year-old male was diagnosed with IgG kappa plasmocytoma 15 months earlier, exhibiting an extensive bone marrow infiltration of more than 60%. A renal involvement was suspected by a proteinuria of 1.8 g/die, including a Bence-Jones proteinuria, and a chronic renal insufficiency stage 3 without further evaluation of the underlying renal disease. After implantation of a central port-catheter system he received a chemotherapeutic regime consisting of vincristine, doxorubicin and dexamethasone for the next four months. His excellent physical constitution allowed the subsequent autologous bone marrow transplantation eight months later. As renal insufficiency progressed, an autologous arteriovenous fistula was created pre-emptively. Six months later he presented with a conspicuous weight loss, a hypercalcaemic crisis and acute renal failure. On clinical examination the patient was afebrile. The cardiac auscultation revealed a pansystolic murmur, first described three years before, suggesting a mitral valve insufficiency. His initial laboratory panel showed a pronounced hypercalcaemia of 3.8 mmol/l (reference range: 2.0 - 2.6 mmol/l), a serum phosphate level of 16 mg/dl (reference range: 2.6 - 4.5 mg/dl), a serum creatinine of 7.9 mg/dl (reference range: 0.5 - 1.1 mg/dl) and a C-reactive protein (CRP) of 6.1 mg/dl (reference range: < 0.5 mg/dl). Haemodialysis treatment was initiated, followed by ibandronate administration. Serum calcium levels rapidly decreased and the overall condition of the patient improved. However, he developed a varicella-zoster virus infection of the left twelfth thoracic dermatome (Th12) requiring intravenous treatment with acyclovir. The diagnosis was based on the typical clinical findings, including limitation of the skin lesions to the left dermatome Th12, and was confirmed by the dermatology department. The zoster lesions were superficial with small vesicles and bullae, but without haemorrhagic lesions, crusts or any signs of bacterial superinfection. Four days later the patient developed a temperature of 39.5°C and chills. The laboratory findings at this time included a normal leukocyte count, a CRP level of 13.2 mg/dl, which further increased on the following day and persisted over 20 mg/dl. Urine examination, an abdominal ultrasound examination, a computed tomography of chest and cranium as well as a three phase bone scan could not reveal the infectious focus. On clinical examination there was no change of the known cardiac murmur and no signs of septic embolization or skin lesions other than his zoster lesions. The latter by now included haemorrhagic vesicle extending to the dermis, disseminated pustules as well as lesions covered by crusts, but no signs of an erysipel or abscess. The central port and the haemodialysis fistula showed no clinical signs of infection. Four sets of aerobic and anaerobic blood cultures were taken from each the peripheral veins as well as from the central port, which was used for the first time since approximately 6 months to draw the blood cultures. An intravenous antibiotic therapy was started with piperacillin/combactam (3 × 2.5 g/day), ciprofloxacin (2 × 250 mg/day) and vancomycin (initial dose 1 g). All blood cultures showed rapid bacterial growth within few hours. There was no apparent difference in time to positivity between peripheral vein and central port drawn blood cultures. Microscopy revealed a gram-positive, but coagulase-negative staphylococcus. Despite early antibiotic treatment, the patient's condition rapidly deteriorated, impeding the realisation of a transoesophageal echocardiogram to exclude endocarditis. The patient died 48 hours after onset of clinical symptoms. Unfortunately, an autopsy was strictly refused by the patient's relatives. The antibiotic susceptibility pattern arrived on the day of death, 48 hours after the beginning of antibiotic treatment. Except for a resistance towards penicillin, the isolated microorganism was sensitive to all antimicrobial agents tested (isoxazolyl penicillin, piperacillin/tacobactam, cefazolin, cefuroxim, imipenem, erythromycin, clindamycin, gentamycin, cotrimoxazol, doxycyclin, ciprofloxacin, levofloxacin, fosfomycin, fusidic acid, linezolid, vancomycin, rifampicin) including all three antibiotics primarily administered. At the same time, the isolated CoNS was identified as S. lugdunensis by polymerase chain reaction.

Discussion and review of the literature

Staphylococcus lugdunensis belongs to the family of CoNS and is frequently found as skin commensal of the perineal region and inguinal folds [46]. Yet it cannot be considered a typical member of the CoNS family as it increasingly has become known for nosocomial and community-acquired infections with a rather aggressive course and a high mortality rate, mirroring the virulent coagulase-positive Staphylococcus aureus. Most frequently, S. lugdunensis isolates were detected with left-sided native valve endocarditis, less frequent prosthetic valve endocarditis, pacemaker-related endocarditis or myocarditis [10, 1419]. In addition, skin and soft tissue infections have been described [5], rarely blood stream infections including sepsis or septic shock [20], bone and joint infections [8, 21, 22], central nervous system infections [23], peritonitis [24, 25], urinary tract [26] or ocular infections [27]. Despite its apparent virulence, only case reports or small patient studies have been published since 1989. Only recently publications on fatal infections emerge and highlight the pathological potential of this atypical CoNS [3]. The low incidence in the past might be explained by the fact that most microbiology laboratories do not routinely identify CoNS isolates to the species level. Yet case of severe sepsis caused by an CoNS with an unusually sensitive antibiotic susceptibility pattern the suspicion for S. lugdunensis should be raised.

S. lugdunensis is a gram-positive, catalase-positive coccus, occurring singly, in pairs or short chains with varying colony morphology and pigmentation [1]. Despite the lack of secreted coagulase, some S. lugdunensis strains express a membrane-bound coagulase, leading to a positive clumping test, which usually indicates S. aureus [28]. In addition, a fibrinogen binding surface protein (Fbl) with considerable similarity to clumping factor A (ClfA) of S. aureus is expressed, which promotes bacterial adhesion to immobilized fibrinogen in animal models of endocarditis [29]. Some isolates demonstrate hemolysis on blood agar when streaked in proximity with beta-hemolytic staphylococcal strains [30, 31]. Other identified virulence factors of S. lugdunensis include the production of an esterase and a lipase as well as the ability to bind extracellular matrix proteins, such as collagen type I and IV, thrombospondin, plasminogen, fibronectin, vitronectin, laminin and human IgG [32, 33]. S. lugdunensis produces tannase, which degrades bacteriostatic and toxic tannins secreted by many microorganisms of the gastrointestinal tract [34]. The accessory gene regulator (agr) system, which has been identified in different staphylococcus strains as regulators of virulence factors, is also detectable in S. lugdunensis, but its impact on the reported virulence still needs to be elucidated [35]. Thus, the CoNS-associated ability of S. lugdunensis to colonize and form biofilms on the surfaces of medical devices combined with virulence factors, which are more reminiscent of S. aureus, highlight the pathogenic potential of this organism.

S. ludgunensis can be identified by conventional biological methods such as pyrrolidonyl arylamidase (PYR) activity, the presence of ornithine decarboxylase and a correct interpretation of the oxcillin minimal inhibitory concentration (MIC) test [28]. The introduction of a characteristic Eikenella corrodens-like odor on Colombia sheep blood agar combined with colony pleomorphism and prominent ß-hemolysis after 2 days of incubation, confirmed by API-ID-32 Staph to further analyze CoNS, led to an 11-fold increase in detection of S. lugdunensis isolates in skin and soft tissue infections in a Danish community [36]. These traditional microbiologic tests are effective, but timely for an accurate identification of this aggressive CoNS. In case of a fulminant septic course the diagnosis comes too late to influence outcome. Alternatively S. lugdunensis can be identified by molecular methods such as an analysis of ribosomal ribonucleic acid (rRNA) restriction fragment length polymorphism [28], real-time polymerase chain reaction (PCR) assays which amplify the 16S rRNA sequence [37] or blot hybridization of a 600-base-pair sequence of the heat shock protein gene (hsp60) [38]. In recent publications conventional [39] as well as quantitative multiplex real-time PCR assays [40] identify S. lugdunensis by amplification of the fbl gene, which encodes a fibrinogen-binding protein, or the tanA gene [41] for tannase.

S. lugdunensis isolates exhibit susceptibility towards a large number of antibiotics in MIC tests, often including penicillin, macrolides, cephalosporins, β-lactams, aminoglycosides, chinolons, rifampicin, fosfomycin, glycopeptides, sulphonamides, chloramphenicol and others [42, 43]. Only few isolates with βlactamase activity or oxacillin-resistance [3] have been described. Nevertheless, our patient died despite an early and appropriate antibiotic treatment with vancomycin, piperacillin/combactam and ciprofloxacin. How can such a virulence be explained despite a high susceptibility to most antibiotics? With regard to vancomycin, Frank et al. described a vancomycin tolerance of 93% of clinical S. lugdunensis isolates despite susceptibility in the in vitro testing, as defined by a minimal bactericidal concentration (MBC)/MIC ratio of ≥ 32 [42]. This tolerance to vancomycin and teicoplanin was verified by time-kill curve methodology [43]. In contrast to glycopeptides, linezolid was successfully employed in the recent past [11, 42]. Thus, if a S. lugdunensis infection is suspected, a combined antimicrobial therapy should be considered which includes linezolid. It is absolutely critical to identify S. lugdunensis as fast as possible by applying the new PCR-based methods described above in contrast to much more time-requiring microbiological tests.

In our patient the source of the S. lugdunensis infection can only be a matter of speculation, as a postmortem autopsy was denied. An endocarditis without any embolic signs or alteration of the heart murmur seems unlikely. Furthermore, the rapid course, mirroring a septic shock, argues against an endocarditis. S. lugdunensis has been reported to be responsible for vascular catheter-related bloodstream infections (CRBSI) [20]. Yet in our patient the central catheter initially did not raise any suspicion of infection and was used for the first time in six months to draw the blood cultures. In addition, both diagnostic criteria to confirm a CRBSI diagnosis, as defined by the Infectious Diseases Society of America [45], are not fulfilled: the ratio of positive blood cultures drawn through the port and through a peripheral vein was 1:1 and not as suggested for CRBSI 5:1 or above. The second criterion of differential time to positivity, which means blood cultures drawn from a central venous catheter to become positive two hours earlier than simultaneously drawn blood cultures from a peripheral vein, was equally not met, arguing against a CRBSI in our case. There are several factors indicating that the herpetic lesions are the most probable site of bacterial entrance. S. lugdunensis is capable and known to cause soft tissue infections and abscesses [5]. The zoster infection preceded the fatal septicaemia by 4-6 days. The herpetic lesions localized at the pelvic girdle region, known to host S. lugdunensis as skin commensal. They showed multiple breaks in the skin surface, allowing the entrance of bacteria. Most importantly, the herpetic lesions included disseminated pustules as sign for a bacterial superinfection.

There are striking clinical similarities to a recently reported concomitant S. lugdunensis and cytomegalovirus infection in an immune deficient patient with scleroderma [10], which is suggestive for a common infectious pathway. Both patients were immunosuppressed, featured a co-infection with S. lugdunensis and a herpes virus, showed a systemic inflammatory response syndrome (SIRS) and rapidly died despite an appropriate antibiotic therapy. Bacterial superinfections of zoster lesions and secondary bacterial infections following respiratory viral infection are common, but the phenomenon of "lethal synergism" is an intriguing new pathogenic mechanism and was first proposed by Beadling and Slifka in 2004 [46]. Different murine models were established to further analyze this mechanism and suggest several factors to cause the high and rapid lethality: a thousandfold increased bacterial titer in solid organs during an acute viral challenge, an increased inflammatory cytokine production or a reduced antibacterial granulocyte defence as a consequence of the innate antiviral immune response [4648]. Given the aggravating value of coinfections between influenza virus and S. aureus, it is tempting to speculate that a similar situation exists in coinfections with S. lugdunensis and herpes viruses.

Conclusion

Here we report a case of fulminant and fatal septicaemia with S. lugdunensis, following a pelvic varicella-zoster virus infection in an immune-deficient patient. The most likely bacterial entry site was a bacterial superinfection of herpes zoster lesions of dermatome Th12. Despite S. lugdunensis belonging to the group of CoNS with a usually low virulence, infections with S. lugdunensis have recently been associated with an aggressive course and high mortality. Therefore early identification and begin of an appropriate antibiotic therapy which includes linezolid seem crucial for the patient's survival. To allow a true judgement on incidence estimation of S. lugdunensis infections as well as their clinical course, CoNS in infective isolates should always be characterized to the underlying species, especially when the antibiotic susceptibility pattern reveals a rather unusual susceptibility to most antimicrobial agents. Furthermore, in case of a suspected S. lugdunensis infection, vancomycin should not be considered as the antimicrobial agent of choice with regard to the reported in vivo tolerance of S. lugdunensis to glycopeptides.

Authors’ Affiliations

(1)
Department of Nephrology, Heinrich-Heine-University
(2)
Department of Radiation Therapy and Radiation Oncology, University of Duesseldorf
(3)
Department of General Surgery, University of Duesseldorf
(4)
Institute of Hygiene and Microbiology, Department of Medical Microbiology, University of Bochum

References

  1. Freney J, Brun Y, Bes M, et al.: Staphylococcus lugdunensis sp. nov. and Staphylococcus schleiferi sp. nov., Two Species from human clinical specimens. Int J Sys Microbiol 1988, 38: 168–172.Google Scholar
  2. Huebner J, Goldmann DA: Coagulase-negative staphylococci: role as pathogens. Annu Rev Med 1999, 50: 223–236. 10.1146/annurev.med.50.1.223PubMedView ArticleGoogle Scholar
  3. Frank KL, Del Pozo JL, Patel R: From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis. Clin Microbiol Rev 2008, 21: 111–133. 10.1128/CMR.00036-07PubMed CentralPubMedView ArticleGoogle Scholar
  4. Bieber L, Kahlmeter G: Staphylococcus lugdunensis in several niches of the normal skin flora. Clin Microbiol Infect 2010,16(4):385–386. 10.1111/j.1469-0691.2009.02813.xPubMedView ArticleGoogle Scholar
  5. Bellamy R, Barkham T: Staphylococcus lugdunensis infection sites: predominance of abscesses in the pelvic girdle region. Clin Infect Dis 2002, 35: E32-E34. 10.1086/341304PubMedView ArticleGoogle Scholar
  6. van der Mee-Marquet N, Achard A, Mereghetti L, Dan-ton A, Minier M, Quentin R: Staphylococcus lugdunensis infections: high frequency of inguinal area carriage. J Clin Microbiol 2003, 41: 1404–1409. 10.1128/JCM.41.4.1404-1409.2003PubMed CentralPubMedView ArticleGoogle Scholar
  7. Kourbeti IS, Alegakis DE, Roditakis GE, Samonis G: Staphylococcus lugdunensis early prosthetic valve endocarditis in a young HIV positive patient. Infection 2007, 35: 40–42. 10.1007/s15010-007-6029-8PubMedView ArticleGoogle Scholar
  8. Murdoch DR, Everts RJ, Chambers ST, Cowan IA: Vertebral osteomyelitis due to Staphylococcus lugdunensis. J Clin Microbiol 1996, 34: 993–994.PubMed CentralPubMedGoogle Scholar
  9. Patel R, Piper KE, Rouse MS, Uhl JR, Cockerill FR, Steckelberg JM: Frequency of isolation of Staphylococcus lugdunensis among staphylococcal isolates causing endocarditis: a 20-year experience. J Clin Microbiol 2000, 38: 4262–4263.PubMed CentralPubMedGoogle Scholar
  10. Pirila L, Soderstrom KO, Hietarinta M, Jalava J, Kyto V, Toivanen A: Fatal myocardial necrosis caused by Staphylococcus lugdunensis and cytomegalovirus in a patient with scleroderma. J Clin Microbiol 2006, 44: 2295–2297. 10.1128/JCM.00002-06PubMed CentralPubMedView ArticleGoogle Scholar
  11. Merino P, Arribi A, Gestoso I, Picazo J, Gimeno L, Del Potro E: Linezolid treatment of a prosthetic joint infection with Staphylococcus lugdunensis in a patient with multiple myeloma. Int J Antimicrob Agents 35: 203–204.Google Scholar
  12. Farrag N, Lee P, Gunney R, Viagappan GM: Staphylococcus lugdunensis endocarditis. Postgrad Med J 2001, 77: 259–260. 10.1136/pmj.77.906.259PubMed CentralPubMedView ArticleGoogle Scholar
  13. Sotutu V, Carapetis J, Wilkinson J, Davis A, Curtis N: The "surreptitious Staphylococcus": Staphylococcus lugdunensis endocarditis in a child. Pediatr Infect Dis J 2002, 21: 984–986. 10.1097/00006454-200210000-00023PubMedView ArticleGoogle Scholar
  14. Etienne J, Pangon B, Leport C, et al.: Staphylococcus lugdunensis endocarditis. Lancet 1989, 1: 390.PubMedView ArticleGoogle Scholar
  15. Petzsch M, Leber W, Westphal B, Crusius S, Reisinger EC: Progressive Staphylococcus lugdunensis endocarditis despite antibiotic treatment. Wien Klin Wochenschr 2004, 116: 98–101. 10.1007/BF03040704PubMedView ArticleGoogle Scholar
  16. Van Hoovels L, De Munter P, Colaert J, et al.: Three cases of destructive native valve endocarditis caused by Staphylococcus lugdunensis. Eur J Clin Microbiol Infect Dis 2005, 24: 149–152. 10.1007/s10096-005-1280-3PubMedView ArticleGoogle Scholar
  17. Anguera I, Del Rio A, Miro JM, et al.: Staphylococcus lugdunensis infective endocarditis: description of 10 cases and analysis of native valve, prosthetic valve, and pacemaker lead endocarditis clinical profiles. Heart 2005, 91: e10. 10.1136/hrt.2004.040659PubMed CentralPubMedView ArticleGoogle Scholar
  18. Laguno M, Miro O, Font C, de la Sierra A: Pacemaker-related endocarditis. Report of 7 cases and review of the literature. Cardiology 1998, 90: 244–248. 10.1159/000006852PubMedView ArticleGoogle Scholar
  19. Seifert H, Oltmanns D, Becker K, Wisplinghoff H, von Eiff C: Staphylococcus lugdunensis pacemaker-related infection. Emerg Infect Dis 2005, 11: 1283–1286. 10.3201/eid1108.041177PubMed CentralPubMedView ArticleGoogle Scholar
  20. Tee WS, Soh SY, Lin R, Loo LH: Staphylococcus lugdunensis carrying the mecA gene causes catheter-associated bloodstream infection in premature neonate. J Clin Microbiol 2003, 41: 519–520. 10.1128/JCM.41.1.519-520.2003PubMed CentralPubMedView ArticleGoogle Scholar
  21. Sampathkumar P, Osmon DR, Cockerill FR: Prosthetic joint infection due to Staphylococcus lugdunensis. Mayo Clin Proc 2000, 75: 511–512.PubMedView ArticleGoogle Scholar
  22. Grupper M, Potasman I, Rosner I, Slobodin G, Rozenbaum M: Septic arthritis due to Staphylococcus lugdunensis in a native joint. Rheumatol Int 2009, in press.Google Scholar
  23. Kaabia N, Scauarda D, Lena G, Drancourt M: Molecular identification of Staphylococcus lugdunensis in a patient with meningitis. J Clin Microbiol 2002, 40: 1824–1825. 10.1128/JCM.40.5.1824-1825.2002PubMed CentralPubMedView ArticleGoogle Scholar
  24. Ludlam H, Phillips I: Staphylococcus lugdunensis peritonitis. Lancet 1989, 2: 1394.PubMedView ArticleGoogle Scholar
  25. Schnitzler N, Meilicke R, Conrads G, Frank D, Haase G: Staphylococcus lugdunensis: report of a case of peritonitis and an easy-to-perform screening strategy. J Clin Microbiol 1998, 36: 812–813.PubMed CentralPubMedGoogle Scholar
  26. Haile DT, Hughes J, Vetter E, et al.: Frequency of isolation of Staphylococcus lugdunensis in consecutive urine cultures and relationship to urinary tract infection. J Clin Microbiol 2002, 40: 654–656. 10.1128/JCM.40.2.654-656.2002PubMed CentralPubMedView ArticleGoogle Scholar
  27. Chiquet C, Pechinot A, Creuzot-Garcher C, et al.: Acute postoperative endophthalmitis caused by Staphylococcus lugdunensis. J Clin Microbiol 2007, 45: 1673–1678. 10.1128/JCM.02499-06PubMed CentralPubMedView ArticleGoogle Scholar
  28. Bannermann TL, Peacock SJ: Staphylococcus, Micrococcus, and other catalase-positive cocci. In Manual of clinical microbiology. 9th edition. Edited by: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA. Washington, DC.: ASM Press; 2007:390–411.Google Scholar
  29. Geoghegan JA, Ganesh VK, Smeds E, Liang X, Hook M, Foster TJ: Molecular characterization of the interaction of staphylococcal MSCRAMMS CLFA and FBL with fibrinogen. J Biol Chem 2010,285(9):6208–6216. 10.1074/jbc.M109.062208PubMed CentralPubMedView ArticleGoogle Scholar
  30. Hebert GA: Hemolysins and other characteristics that help differentiate and biotype Staphylococcus lugdunensis and Staphylococcus schleiferi. J Clin Microbiol 1990, 28: 2425–2431.PubMed CentralPubMedGoogle Scholar
  31. Vandenesch F, Storrs MJ, Poitevin-Later F, Etienne J, Courvalin P, Fleurette J: Delta-like haemolysin produced by Staphylococcus lugdunensis. FEMS Microbiol Lett 1991, 62: 65–68.PubMedGoogle Scholar
  32. Lambe DW Jr, Ferguson KP, Keplinger JL, Gemmell CG, Kalbfleisch JH: Pathogenicity of Staphylococcus lugdunensis, Staphylococcus schleiferi, and three other coagulase-negative staphylococci in a mouse model and possible virulence factors. Can J Microbiol 1990, 36: 455–463. 10.1139/m90-080PubMedView ArticleGoogle Scholar
  33. Paulsson M, Petersson AC, Ljungh A: Serum and tissue protein binding and cell surface properties of Staphylococcus lugdunensis. J Med Microbiol 1993, 38: 96–102. 10.1099/00222615-38-2-96PubMedView ArticleGoogle Scholar
  34. Noguchi N, Ohashi T, Shiratori T, et al.: Association of tannase-producing Staphylococcus lugdunensis with colon cancer and characterization of a novel tannase gene. J Gastroenterol 2007, 42: 346–351. 10.1007/s00535-007-2012-5PubMedView ArticleGoogle Scholar
  35. Donvito B, Etienne J, Greenland T, Mouren C, Delorme V, Vandenesch F: Distribution of the synergistic haemolysin genes hld and slush with respect to agr in human staphylococci. FEMS Microbiol Lett 1997, 151: 139–144. 10.1111/j.1574-6968.1997.tb12562.xPubMedView ArticleGoogle Scholar
  36. Böcher S, Tonning B, Skov R, Prag J: Staphylococcus lugdunensis, a common cause of skin and soft tissue infections in the community. J Clin Microbiol 2009,47(4):946–650. 10.1128/JCM.01024-08PubMed CentralPubMedView ArticleGoogle Scholar
  37. Skow A, Mangold KA, Tajuddin M, et al.: Species-level identification of staphylococcal isolates by real-time PCR and melt curve analysis. J Clin Microbiol 2005, 43: 2876–2880. 10.1128/JCM.43.6.2876-2880.2005PubMed CentralPubMedView ArticleGoogle Scholar
  38. Goh SH, Potter S, Wood JO, Hemmingsen SM, Reynolds RP, Chow AW: HSP60 gene sequences as universal targets for microbial species identification: studies with coagulase-negative staphylococci. J Clin Microbiol 1996, 34: 818–823.PubMed CentralPubMedGoogle Scholar
  39. Pereira EM, Oliveira FL, Schuenck RP, Zoletti GO, Dos Santos KR: Detection of Staphylococcus lugdunensis by a new species-specific PCR based on the fbl gene. FEMS Immunol Med Microbiol 2009.Google Scholar
  40. Pinsky BA, Samson D, Ghafghaichi L, Baron EJ, Banaei N: Comparison of real-time PCR and conventional biochemical methods for identification of Staphylococcus lugdunensis. J Clin Microbiol 2009, 47: 3472–3477. 10.1128/JCM.00342-09PubMed CentralPubMedView ArticleGoogle Scholar
  41. Noguchi N, Goto K, Ro T, et al.: Using the tannase gene to rapidly and simply identify Staphylococcus lugdunensis. Diagn Microbiol Infect Dis 66: 120–123.Google Scholar
  42. Frank KL, Reichert EJ, Piper KE, Patel R: In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates. Antimicrob Agents Chemother 2007, 51: 888–895. 10.1128/AAC.01052-06PubMed CentralPubMedView ArticleGoogle Scholar
  43. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT: In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob Agents Chemother 2006, 50: 3959–3962. 10.1128/AAC.00722-06PubMed CentralPubMedView ArticleGoogle Scholar
  44. Bourgeois I, Pestel-Caron M, Lemeland JF, Pons JL, Caron F: Tolerance to the glycopeptides vancomycin and teicoplanin in coagulase-negative staphylococci. Antimicrob Agents Chemother 2007, 51: 740–743. 10.1128/AAC.00719-06PubMed CentralPubMedView ArticleGoogle Scholar
  45. Mermel LA, Farr BM, Sherertz RJ, et al.: Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001, 32: 1249–1272. 10.1086/320001PubMedView ArticleGoogle Scholar
  46. Beadling C, Slifka MK: How do viral infections predispose patients to bacterial infections? Curr Opin Infect Dis 2004, 17: 185–191. 10.1097/00001432-200406000-00003PubMedView ArticleGoogle Scholar
  47. Centers for Disease Control and Prevention (CDC): Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007, 56: 325–329.Google Scholar
  48. Navarini AA, Recher M, Lang KS, et al.: Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responses. Proc Natl Acad Sci USA 2006, 103: 15535–15539. 10.1073/pnas.0607325103PubMed CentralPubMedView ArticleGoogle Scholar

Copyright

© I. Holzapfel Publishers 2010